文献速递类风湿关节炎血管炎

早期类风湿关节炎中生物制剂与传统合成改善病情抗风湿药治疗的心血管效应比较

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2020-08-28

本研究基于一项IV期早期类风湿关节炎随机对照试验,比较一线依那西普联合甲氨蝶呤与甲氨蝶呤策略对心血管的影响。结果显示,与匹配对照相比,早期类风湿关节炎患者基线主动脉扩张性降低、左心室质量降低、心肌细胞外容积增加;在所有患者中,主动脉扩张性从基线至第1年显著改善并维持至第2年,且改善程度在两种治疗策略及不同疾病活动度应答状态间无差异。

要点

  • 早期类风湿关节炎患者存在血管和心肌异常,表现为主动脉扩张性降低、左心室质量降低和心肌细胞外容积增加。
  • 改善病情抗风湿药治疗可改善主动脉扩张性,从基线至第1年显著提高并维持至第2年。
  • 一线依那西普联合甲氨蝶呤与甲氨蝶呤策略对心血管标志物的改善无差异,临床应答状态亦不影响改善程度。

核心结论

  • 首次在早期类风湿关节炎随机对照试验队列中报告血管和心肌异常,并显示改善病情抗风湿药治疗可改善这些异常。
  • 改善病情抗风湿药类型(一线肿瘤坏死因子抑制剂或甲氨蝶呤)及临床应答不影响心血管疾病标志物。

研究设计与样本

  • IV期早期类风湿关节炎试验随机分配至依那西普联合甲氨蝶呤或甲氨蝶呤策略(第6个月可升级至依那西普联合甲氨蝶呤)。
  • 纳入无心血管疾病且传统危险因素不超过1个的患者,在基线、第1年和第2年进行心血管磁共振检查;30名匹配对照接受心血管磁共振检查。
  • 共招募81名患者。

主要发现

  • 基线时早期类风湿关节炎患者较对照的主动脉扩张性显著降低:3.0×10-3 mm Hg-1(95%CI 2.7-3.3)vs 4.4×10-3 mm Hg-1(95%CI 3.7-5.2),p<0.001。
  • 基线时早期类风湿关节炎患者较对照的左心室质量显著降低:78.2 g(95%CI 74.0-82.7,n=81)vs 92.9 g(95%CI 84.8-101.7,n=30),p<0.01。
  • 基线时早期类风湿关节炎患者较对照的心肌细胞外容积增加:27.1%(95%CI 26.4-27.9,n=78)vs 24.9%(95%CI 23.8-26.1,n=30),p<0.01。
  • 所有患者主动脉扩张性从基线至第1年显著改善:3.0×10-3 mm Hg-1(95%CI 2.7-3.4)至3.6×10-3 mm Hg-1(95%CI 3.1-4.1),p<0.01,并维持至第2年。
  • 主动脉扩张性改善在两种治疗组间及疾病活动度应答者与非应答者间无差异。

临床怎么用

  • 早期类风湿关节炎患者应关注血管和心肌异常,改善病情抗风湿药治疗可能改善主动脉扩张性。
  • 一线选择依那西普联合甲氨蝶呤或甲氨蝶呤策略对心血管标志物的改善无差异,临床决策时可综合考虑其他因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine whether patients with early rheumatoid arthritis (ERA) have cardiovascular disease (CVD) that is modifiable with disease-modifying antirheumatic drug (DMARD) therapy, comparing first-line etanercept (ETN) + methotrexate (MTX) with MTX strategy. METHODS: Patients from a phase IV ERA trial randomised to ETN+MTX or MTX strategy±month 6 escalation to ETN+MTX, and with no CVD and maximum one traditional risk factor underwent cardiovascular magnetic resonance (CMR) at baseline, years 1 and 2. Thirty matched controls underwent CMR. Primary outcome measure was aortic distensibility (AD) between controls and ERA, and baseline to year 1 AD change in ERA. Secondary analyses between and within ERA groups performed. Additional outcome measures included left ventricular (LV) mass and myocardial extracellular volume (ECV). RESULTS: Eighty-one patients recruited. In ERA versus controls, respectively, baseline (geometric mean, 95% CI) AD was significantly lower (3.0×10-3 mm Hg-1 (2.7-3.3) vs 4.4×10-3 mm Hg-1 (3.7-5.2), p<0.001); LV mass significantly lower (78.2 g (74.0-82.7), n=81 vs 92.9 g (84.8-101.7), n=30, p<0.01); and ECV increased (27.1% (26.4-27.9), n=78 vs 24.9% (23.8-26.1), n=30, p<0.01). Across all patients, AD improved significantly from baseline to year 1 (3.0×10-3 mm Hg-1 (2.7-3.4) to 3.6×10-3 mm Hg-1 (3.1-4.1), respectively, p<0.01), maintained at year 2. The improvement in AD did not differ between the two treatment arms and disease activity state (Disease Activity Score with 28 joint count)-erythrocyte sedimentation rate-defined responders versus non-responders. CONCLUSION: We report the first evidence of vascular and myocardial abnormalities in an ERA randomised controlled trial cohort and show improvement with DMARD therapy. The type of DMARD (first-line tumour necrosis factor-inhibitors or MTX) and clinical response to therapy did not affect CVD markers. TRIAL REGISTRATION NUMBER: ISRCTN: ISRCTN89222125; ClinicalTrials.gov: NCT01295151.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Plein S, Erhayiem B, Fent G, et al. Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis. Ann Rheum Dis. 2020. PMID: 32859608. doi:10.1136/annrheumdis-2020-217653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。